Wegovy’s new oral obesity pill sparks early optimism as Novo Nordisk stock climbs

Novo Nordisk shares rose over 5% after early prescription data signaled solid initial demand for the company’s new oral GLP-1 Wegovy pill in the U.S.; analysts caution that one data point isn’t a trend, but early-week prescriptions—reported around 3,100 by Leerink and about 4,290 by Symphony—suggest the pill could outpace its injectable rivals at the same stage, even as competition from Eli Lilly’s Zepbound and the upcoming orforglipron enters the market and dosing restrictions may influence uptake.